Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study

By afschroeder • September 20, 2026

Cluzeau T, Borate U, McMahon C, Fenaux P, Heiblig M, Peterlin P, Ball B, Chantepie S, Eghtedar A, Kambhampati S, Solh M, Torregrosa-Diaz J, Braun T, Dugan J, Feld J, Gourin MP, Pigneux A, Robin JB, Schiller G, Stein E, Roth D, Kelly M, Pollyea D, de Botton S. Tamibarotene with venetoclax and azacitidine in RARA⁺ acute myeloid leukemia: results from the SY-1425-202 study. Blood Neoplasia. 2026 Jul 28;3(4):100279. doi: 10.1016/j.bneo.2026.100279. PMID: 42761251; PMCID: PMC13586685.

Tags: Hematology/Oncology, Publications

Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety-Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024

Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S. Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles[...]

Evolution and heterogeneity of lethal metastatic bladder cancer subtypes

Itagi P, Schuster SL, Arora S, Persse TW, Waters JA, Yang M, Min A, Chandra P, Adil M, Galipeau PC, Rudoy D, Kreitman AS, Lin[...]

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov[...]